|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104767 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-23 15:26:40 |
|
注册时间: Date of Registration: |
2025-06-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
心脏手术后ICU谵妄虚拟现实预防系统的效果评价研究 |
|
Public title: |
Evaluation on the Effects of Virtual Reality Prevention System for Delirium in ICU Patients following Cardiac Surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
心脏手术后ICU谵妄虚拟现实预防系统的效果评价研究 |
|
Scientific title: |
Evaluation on the Effects of Virtual Reality Prevention System for Delirium in ICU Patients following Cardiac Surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
那木娜 |
研究负责人: |
吴瑛; 张喜维 |
|
Applicant: |
Namuna Dallakoti |
Study leader: |
Ying Wu; Xiwei Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 157 2474 3478 |
研究负责人电话:
Study leader's |
+86 139 1078 9837 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
namuna2022@163.com |
研究负责人电子邮件: Study leader's E-mail: |
helenywu@vip.163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区右安门街道外西铁营331号 |
研究负责人通讯地址: |
北京市丰台区右安门街道外西铁营331号 |
|
Applicant address: |
Beijing, Fengtai, You Anmen, Jiedao Wai Xi tie Ying 331 |
Study leader's address: |
Beijing, Fengtai, You Anmen, Jiedao Wai Xi tie Ying 331 |
|
申请注册联系人邮政编码: Applicant postcode: |
100069 |
研究负责人邮政编码: Study leader's postcode: |
100069 |
|
申请人所在单位: |
首都医科大学 |
||
|
Applicant's institution: |
Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学 |
||
|
Affiliation of the Leader: |
Capital Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
Z2025SY009/KS2025100 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学医学伦理委员会/首都医科大学附属北京安贞医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-27 00:00:00 | ||
|
伦理委员会联系人: |
刘芳 |
||
|
Contact Name of the ethic committee: |
Liu Fang |
||
|
伦理委员会联系地址: |
10号 右安门 外头条丰台北京中国 |
||
|
Contact Address of the ethic committee: |
No.10?Youanmen waitoutiao,?Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8391 1936 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
首都医科大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
10号 右安门 外头条丰台北京中国 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.10?Youanmen waitoutiao,?Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-raised |
||||||||||||||||||||||
|
研究疾病: |
谵妄 |
||||||||||||||||||||||
|
Target disease: |
Delirium |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在评估术前VR干预对降低ICU谵妄发生率及其他次要结局(包括焦虑水平、谵妄持续时间、ICU/住院时间、死亡率等)的效果 |
||||||||||||||||||||||
|
Objectives of Study: |
Our study aims to determine the effect of the use of VR intervention pre-operatively in decreasing the incidence of ICU delirium and several secondary outcomes, including the anxiety level, the duration of ICU delirium, length of ICU and hospital stay, mortality, and other delirium-related outcomes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
① 年龄≥18周岁的择期心脏手术患者;② 预计住院时间≥24小时。 |
||||||||||||||||||||||
|
Inclusion criteria |
1 Adults aged 18 years or older scheduled for elective cardiac surgery; 2 Expected hospital stay of at least 24 hours. |
||||||||||||||||||||||
|
排除标准: |
① 未经术前住院的急诊心脏手术患者;② 存在认知功能障碍(包括意识状态改变、精神异常或语言/视觉/听觉缺陷);③ 患有影响认知功能的神经精神疾病;④ 酒精滥用史;⑤ 前庭功能障碍或晕动症病史;⑥ 无法耐受综合干预措施;⑦ 当前参与其他临床试验;⑧ 拒绝参与或无法签署知情同意书;⑨ 无法使用普通话或英语沟通。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1 Patients undergoing emergency cardiac surgery without prior hospitalization; 2 Patients with cognitive impairments, including altered consciousness, impaired mental status, or deficits in language, vision, or hearing; 3 Patients with neuropsychiatric disorders affecting cognitive function; 4 Patients with a history of alcohol abuse; 5 Patients with a history of vestibular dysfunction or motion sickness; 6 Patients unable to tolerate the comprehensive intervention measures; 7 Patients currently enrolled in other ongoing clinical trials; 8 Patients who refuse to participate or are unable to provide informed consent; 9 Patients unable to communicate in either Mandarin Chinese or English. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2026-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-07-01 00:00:00 至 To 2026-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用置换区组随机化方法,设置4、6、8、10的变长区组,以确保干预组(接受虚拟现实ICU环境模拟联合AI-AntiDelirium护理)与对照组(仅接受AI-AntiDelirium护理)按1:1比例均衡分配。每个区组内两组人数相等(如区组大小为4时2:2分配,区组大小为6时3:3分配),并通过随机排列分配顺序降低可预测性和选择偏倚。随机序列由独立第三方使用R统计软件(4.5版)的blockrand程序包生成,该人员不参与受试者招募、干预实施或结局评估。根据该序列,研究团队将预先制备密封、不透光、按序编号的信封。每个信封仅标注与入组顺序对应的受试者编号(如患者001、002等)。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The randomization sequence will be generated using R statistical software (version 4.5) with the blockrand package by an independent third party who will not be involved in participant recruitment, intervention delivery, or outcome assessment. Based on this sequence, a set of sealed, opaque, and sequentially numbered envelopes will be prepared in advance. Each envelope will be labeled only with a participant identification number corresponding to the order of enrollment (e.g., Patient 001, 002, etc.). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
虽然无法实现完全盲法,但通过严格执行标准化操作流程、统一应用评估工具、以及仅采用经过验证的量表,可最大限度减少潜在偏倚。由单一经培训的研究者同时承担干预与评估任务虽有助于保持内部一致性、降低评估者间变异,但可能引入主观偏倚,该局限性将在研究中予以明确说明。 |
|
Blinding: |
Due to the nature of the intervention, blinding of both the participant and the investigator is not feasible. The same researcher (the principal investigator) will deliver the intervention and conduct all outcome assessments using validated tools, including the iCAM-ICU, MMSE, Barthel Index (BI), and Sedation-Agitation Scale (SAS). Participants will be instructed not to discuss their group assignment during assessments to help reduce observer bias. Although full blinding is not possible, potential bias will be minimized through strict adherence to standardized protocols, consistent application of outcome measures, and the exclusive use of validated tools. The involvement of a single trained researcher in both intervention and assessment tasks may enhance internal consistency by reducing inter-rater variability; however, this approach also introduces the risk of subjective bias, which will be transparently acknowledged as a limitation in the study. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
N/A |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据收集将由主要研究者负责,该研究者对干预措施的实施和结局评估均承担唯一责任。为确保数据一致性并最大限度减少观察者间变异,所有数据将采用标准化的病例报告表进行收集,并录入至安全的电子数据库(AI-Antidelirium工具,Excel)。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection will be carried out by the principal investigator, who is solely responsible for both administering the intervention and conducting outcome assessments. To ensure consistency and minimize inter-observer variability, all data will be collected using standardized case report forms and entered into a secure electronic database (AI-Antidelirium Tool, Excel). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |